| 查看: 129 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】XOMA Reviews Priorities for 2010 and 2009 Accomplishments
|
||
|
XOMA Reviews Priorities for 2010 and 2009 Accomplishments BERKELEY, Calif., Jan 19, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today provided a summary of its priorities for 2010 and accomplishments during 2009. "In 2009, we continued to advance our lead product candidate, XOMA 052, an antibody to interleukin-1 beta (IL-1 beta), into Phase 2 development as a potentially paradigm-shifting anti-inflammatory approach to the treatment of Type 2 diabetes and cardio-metabolic diseases," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "Most significantly, we expanded the XOMA 052 program beyond our focus on diabetes to cardiovascular disease. This expansion was supported by results from our Phase 1 trials demonstrating benefit in biomarkers of cardiovascular disease, animal studies evaluating XOMA 052 in cardio-metabolic disease models, and studies with other IL-1 targeting agents that have shown the potential for cardiovascular benefit from IL-1 inhibition, some results of which are expected to be presented at the American College of Cardiology meeting in March." |
回复此楼» 猜你喜欢
一志愿浙大药学求调剂
已经有1人回复
-
070700求调剂
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有256人回复
-
高温高压反应求助
已经有4人回复
-
求调剂总分327
已经有1人回复
-
药学B区求调剂
已经有4人回复
-
重庆医科大学-人工智能医学学院
已经有0人回复
-
重庆医科大学-人工智能医学学院
已经有1人回复
-
丽水学院材料与能源工程学院招收调剂！（可调剂专业范围广）
已经有0人回复
-
晴川万里新书
已经有4人回复
